Notice of Proposed Sale · 144
Xeris Biopharma Holdings, Inc.
XERSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- XERIS BIOPHARMA HOLDINGS, INC.
- Issuer CIK
- 0001867096
- SEC file number
- 001-40880
- Phone
- 8444455704
- Person for whose account securities are to be sold
- KEVIN MCCULLOCH
- Relationships to issuer
- Officer
- Street
- 1375 West Fulton Street, Suite 1300
- City
- Chicago
- State / country code
- IL
- Postal code
- 60607
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 120,000 | 950,400.00 | 172,642,055 | 07/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 01/29/2024 | Restricted Stock Units | Issuer | 120,000 | N | 01/29/2024 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/29/2024 through 01/31/2025.
Notice signature
- Notice date
- 07/01/2026
- Signed
- /s/ Kevin McCulloch
- Plan adoption dates
- 09/04/2025